Tag: pertussis vaccine market share

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Pertussis Vaccine Market Revenue Outlook: What CAGR Lies Ahead Through 2030?

The pertussis vaccine market has shown consistent expansion in recent years. Its valuation is set to increase from $5.65 billion in 2025 to $5.82 billion in 2026, achieving a compound annual growth rate (CAGR) of 2.9%. The historical expansion of this market can be attributed to factors such as extensive childhood immunization coverage, government-supported national vaccination programs, past outbreaks of whooping cough, the integration of the pertussis vaccine into standard immunization schedules, and the availability of whole-cell vaccines.

The pertussis vaccine market size is projected to experience consistent expansion over the upcoming years. This market is forecast to reach $6.82 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.1%. This anticipated growth during the forecast period is attributable to several factors, including heightened awareness regarding adult pertussis vaccination, an increase in recommendations for maternal immunization, improvements in vaccine safety and effectiveness, broader access to healthcare in developing economies, and the advancement of combination vaccine development. Key trends anticipated during this period encompass the increasing acceptance of acellular pertussis vaccines, a greater emphasis on booster immunization programs, the broadening scope of combination vaccines that incorporate pertussis, an increase in adult and maternal pertussis vaccination, and the reinforcement of government-led immunization efforts.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=31366900&type=smp&name=Pertussis%20Vaccine%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Pertussis Vaccine Market Industry Drivers: What’s Behind The Revenue Growth?

The increasing childbirth rates are poised to boost the growth of the pertussis vaccine market in the upcoming period. Childbirth is defined as the act of a mother giving birth to a baby. It represents the conclusion of pregnancy, during which the fetus develops inside the mother’s uterus, marking the beginning of an independent life outside the womb. The pertussis vaccine is primarily administered to children to protect them from whooping cough and other severe, potentially fatal diseases. As an illustration, a report released by the Centers for Disease Control and Prevention, a US-based national public health organization, in January 2023, showed that the United States experienced a 1% rise in registered births, amounting to 3,664,292, compared to 2022. Consequently, the escalating childbirth rates are serving as a significant driver for the expansion of the pertussis vaccine market.

Pertussis Vaccine Market Segment Performance And Emerging Opportunities

The pertussis vaccine market covered in this report is segmented –

1) By Product Type: DTaP (Diphtheria, Tetanus and Acellular Pertussis) Vaccine, Tdap (Tetanus, Diphtheria and Pertussis) Vaccine

2) By Vaccine Type: Whole-Cell Vaccine, Acellular Vaccine

3) By Application: Children, Adults, Infants

4) By End-User: Vaccination Centers, Hospitals, Clinics

Subsegments:

1) By DTaP (Diphtheria, Tetanus, And Acellular Pertussis) Vaccine: Pediatric DTaP Vaccine, Combination Vaccines With DTaP

2) By Tdap (Tetanus, Diphtheria, And Pertussis) Vaccine: Adolescent Tdap Vaccine, Adult Tdap Vaccine

#Pertussis Vaccine Market Growth Trends: What’s Shaping The Future Outlook?

Key companies in the pertussis vaccine market are prioritizing the development of advanced immunization solutions and obtaining regulatory clearances to enhance protection for mothers and infants against whooping cough. These endeavors aim to boost vaccine availability, expand their recommended application during pregnancy, and decrease pertussis-related illnesses in newborns. For example, in January 2023, Sanofi S.A., a biopharmaceutical company based in France, received U.S. FDA approval for the broader use of its Adacel (Tdap) vaccine during the third trimester of pregnancy. This enables maternal immunization to help safeguard infants younger than two months, who are most vulnerable to severe pertussis infection. This approval allows healthcare providers to actively vaccinate pregnant individuals, ensuring that protective antibodies are passed to the newborn before birth. As a result, infants gain crucial early-life protection against pertussis, bridging the immunity gap until they can receive their own vaccinations.

Pertussis Vaccine Market Key Players: Which Companies Lead Industry Competition?

Major companies operating in the pertussis vaccine market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Sanofi Pasteur SA, CSL Limited, Serum Institute of India, Biological E. Limited, Bharat Biotech International Limited, Panacea Biotec Limited, PT Bio Farma, Walvax Biotechnology Co. Ltd., Beijing Minhai Biotechnology Co. Ltd., Wuhan Institute of Biological Products, Changchun Changsheng Life Sciences, Changsheng Bio-Technology Co. Ltd., Chiron Corporation, Sinovac Biotech Ltd., Takeda Pharmaceutical Company, Novartis AG, Johnson & Johnson

View The Full Pertussis Vaccine Market Report:

https://thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Pertussis Vaccine Market Geographic Analysis: Where Is Demand Accelerating Fastest?

North America was the largest region in the pertussis vaccine market in 2025. The regions covered in the pertussis vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Pertussis Vaccine Market Value Expansion And Long-Term Growth Outlook

The size of the pertussis vaccine market has experienced consistent expansion in recent times. From $5.65 billion in 2025, it is projected to reach $5.82 billion by 2026, reflecting a compound annual growth rate (CAGR) of 2.9%. Factors driving historical growth include extensive immunization coverage among children, government-sponsored nationwide vaccination initiatives, past episodes of whooping cough outbreaks, the integration of the pertussis vaccine into standard immunization protocols, and the accessibility of whole-cell vaccines.

The pertussis vaccine market is anticipated to experience consistent expansion over the coming years, projected to reach $6.82 billion by 2030, reflecting a compound annual growth rate (CAGR) of 4.1%. This forecasted growth is driven by factors such as heightened awareness regarding adult pertussis vaccination, increased recommendations for maternal immunization, improvements in vaccine safety and effectiveness, broader healthcare access in developing nations, and the advancement of combination vaccine formulations. Key trends shaping this period include the growing preference for acellular pertussis vaccines, a heightened emphasis on booster immunization programs, the development of more combined vaccines containing pertussis elements, expanded vaccination efforts targeting adults and pregnant women, and reinforced government-led immunization campaigns.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13023&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Pertussis Vaccine Market Opportunity Drivers: What Is Creating New Revenue Potential?

The growth of the pertussis vaccine market is being propelled forward by an increase in childbirth rates. Childbirth refers to the process of delivering a baby, signaling the end of a pregnancy where a fetus develops inside the mother’s womb and the start of a new life outside it. This vaccine is mainly administered to children as it shields them from whooping cough and other serious, potentially fatal illnesses. As an example, a January 2023 report from the Centers for Disease Control and Prevention, a U.S.-based national public health agency, revealed that registered births in the United States rose by 1% to 3,664,292 compared to the previous year, 2022. Consequently, the rising number of childbirths is fueling expansion in the pertussis vaccine market.

Pertussis Vaccine Market Segment Analysis Highlighting Growth Areas

The pertussis vaccine market covered in this report is segmented –

1) By Product Type: DTaP (Diphtheria, Tetanus and Acellular Pertussis) Vaccine, Tdap (Tetanus, Diphtheria and Pertussis) Vaccine

2) By Vaccine Type: Whole-Cell Vaccine, Acellular Vaccine

3) By Application: Children, Adults, Infants

4) By End-User: Vaccination Centers, Hospitals, Clinics

Subsegments:

1) By DTaP (Diphtheria, Tetanus, And Acellular Pertussis) Vaccine: Pediatric DTaP Vaccine, Combination Vaccines With DTaP

2) By Tdap (Tetanus, Diphtheria, And Pertussis) Vaccine: Adolescent Tdap Vaccine, Adult Tdap Vaccine

Pertussis Vaccine Market Innovation Trends Driving Future Development

Leading players in the pertussis vaccine industry are concentrating on the creation of cutting-edge immunization strategies and obtaining official approvals to improve protection for both mothers and their newborns against whooping cough. These initiatives seek to boost vaccine availability, extend authorized usage during pregnancy, and decrease pertussis-related illness rates in infants. For example, in January 2023, Sanofi S.A., a biopharmaceutical firm headquartered in France, secured approval from the U.S. FDA for an expanded application of its Adacel (Tdap) vaccine during the third trimester of pregnancy. This move allows maternal vaccination to safeguard infants under two months old—the group most vulnerable to severe pertussis. By immunizing pregnant individuals, healthcare providers can ensure that protective antibodies are transferred to the baby prior to delivery, offering early-life defense against pertussis and filling the immunity gap until the infant’s own vaccinations begin.Leading companies in the pertussis vaccine market are prioritizing the development of advanced immunization methods and obtaining regulatory clearances to improve protection for both mothers and infants against whooping cough. These strategies aim to increase vaccine accessibility, broaden recommended usage during pregnancy, and lower pertussis-related health complications among newborns. For instance, in January 2023, Sanofi S.A., a biopharmaceutical company based in France, received U.S. FDA approval to extend the use of its Adacel (Tdap) vaccine during the third trimester of pregnancy, allowing maternal immunization to protect infants under two months old who face the greatest risk of severe pertussis infection. This approval empowers healthcare providers to vaccinate pregnant individuals, facilitating the transfer of protective antibodies to the baby before birth. Consequently, infants gain early immunity against pertussis, closing the protection gap until they can receive their own vaccinations.

Pertussis Vaccine Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the pertussis vaccine market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Sanofi Pasteur SA, CSL Limited, Serum Institute of India, Biological E. Limited, Bharat Biotech International Limited, Panacea Biotec Limited, PT Bio Farma, Walvax Biotechnology Co. Ltd., Beijing Minhai Biotechnology Co. Ltd., Wuhan Institute of Biological Products, Changchun Changsheng Life Sciences, Changsheng Bio-Technology Co. Ltd., Chiron Corporation, Sinovac Biotech Ltd., Takeda Pharmaceutical Company, Novartis AG, Johnson & Johnson

Access The Complete Pertussis Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Pertussis Vaccine Market Leading Geography: Which Region Generates The Most Revenue?

North America was the largest region in the pertussis vaccine market in 2025. The regions covered in the pertussis vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Are The Forecasted Market Size Figures For The Pertussis Vaccine Market In 2026 And 2030?

The pertussis vaccine market size has consistently increased in recent years. This market is projected to expand from $5.65 billion in 2025 to $5.82 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 2.9%. The growth observed in the historic period can be attributed to high childhood immunization coverage, government-led national vaccination programs, historical outbreaks of whooping cough, the inclusion of the pertussis vaccine in routine immunization schedules, and the availability of whole-cell vaccines.

The pertussis vaccine market is anticipated to experience consistent expansion over the upcoming years. Its value is projected to reach $6.82 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.1%. This growth during the forecast period stems from factors such as increasing awareness regarding adult pertussis vaccination, growing recommendations for maternal immunization, improvements in vaccine safety and effectiveness, broader access to healthcare in developing economies, and increased development of combination vaccines. Key trends identified for the forecast timeframe encompass the increasing acceptance of acellular pertussis vaccines, a greater emphasis on booster immunization campaigns, the proliferation of combination vaccines incorporating pertussis, the expanding scope of adult and maternal pertussis vaccination, and more robust government immunization efforts.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13023&type=smp

Which Strategic Drivers Are Supporting The Pertussis Vaccine Market Development?

The expanding number of births is propelling the growth of the pertussis vaccine market in the foreseeable future. Childbirth refers to the process of a mother delivering a baby, marking the conclusion of pregnancy where the fetus develops within the womb and signals the start of life outside it. This vaccine is mainly administered to children, offering protection against whooping cough and other serious, potentially fatal illnesses. As an illustration, the United States experienced a 1% rise in recorded births, reaching 3,664,292, in January 2023 compared to 2022, as reported by the Centers for Disease Control and Prevention, a US-based national public health organization. Consequently, the increasing childbirth figures are a key factor stimulating the expansion of the pertussis vaccine market.

What Are The Major Segment Categories Within The Pertussis Vaccine Market?

The pertussis vaccine market covered in this report is segmented –

1) By Product Type: DTaP (Diphtheria, Tetanus and Acellular Pertussis) Vaccine, Tdap (Tetanus, Diphtheria and Pertussis) Vaccine

2) By Vaccine Type: Whole-Cell Vaccine, Acellular Vaccine

3) By Application: Children, Adults, Infants

4) By End-User: Vaccination Centers, Hospitals, Clinics

Subsegments:

1) By DTaP (Diphtheria, Tetanus, And Acellular Pertussis) Vaccine: Pediatric DTaP Vaccine, Combination Vaccines With DTaP

2) By Tdap (Tetanus, Diphtheria, And Pertussis) Vaccine: Adolescent Tdap Vaccine, Adult Tdap Vaccine

What Trends Are Impacting The Pertussis Vaccine Market?

Key companies operating in the pertussis vaccine market are focused on developing improved immunization solutions and obtaining regulatory approvals to bolster maternal and infant protection against whooping cough. These efforts are geared towards enhancing vaccine accessibility, expanding their recommended use during pregnancy, and reducing pertussis-related illness in newborns. For example, in January 2023, the France-based biopharmaceutical company Sanofi S.A. received U.S. FDA approval for the expanded use of its Adacel (Tdap) vaccine during the third trimester of pregnancy. This approval facilitates maternal immunization to help protect infants younger than two months, who are at the highest risk of severe pertussis infection. As a result, healthcare providers can actively immunize pregnant individuals, ensuring that protective antibodies are transferred to the newborn before birth. This provides infants with vital early-life protection against pertussis, bridging the immunity gap until they are able to receive their own vaccinations.

Which Companies Are Engaged In The Pertussis Vaccine Market Environment?

Major companies operating in the pertussis vaccine market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Sanofi Pasteur SA, CSL Limited, Serum Institute of India, Biological E. Limited, Bharat Biotech International Limited, Panacea Biotec Limited, PT Bio Farma, Walvax Biotechnology Co. Ltd., Beijing Minhai Biotechnology Co. Ltd., Wuhan Institute of Biological Products, Changchun Changsheng Life Sciences, Changsheng Bio-Technology Co. Ltd., Chiron Corporation, Sinovac Biotech Ltd., Takeda Pharmaceutical Company, Novartis AG, Johnson & Johnson

Access The Complete Pertussis Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

Which Region Is The Primary Market For The Pertussis Vaccine Market?

North America was the largest region in the pertussis vaccine market in 2025. The regions covered in the pertussis vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Pertussis Vaccine Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=13023&type=smp

Browse Through More Reports Similar to the Global Pertussis Vaccine Market 2026, By The Business Research Company

Pertussis Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

Porcine Epidemic Diarrhea Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Pertussis Vaccine Market During The Forecast Period?

The pertussis vaccine market size has consistently expanded in recent years. It is projected to increase from $5.65 billion in 2025 to $5.82 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 2.9%. The market’s expansion historically stems from high childhood immunization coverage, government-driven national vaccination programs, past outbreaks of whooping cough, the integration of the pertussis vaccine into routine immunization schedules, and the availability of whole-cell vaccines.

The pertussis vaccine market is anticipated to experience consistent expansion over the upcoming years. This market is projected to reach $6.82 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.1%. Factors contributing to this growth during the projected timeframe include heightened awareness regarding adult pertussis immunization, a rise in recommendations for maternal vaccination, progress in enhancing vaccine safety and effectiveness, broader access to healthcare within developing nations, and an increase in the development of combination vaccines. Key trends anticipated for the forecast period encompass the increasing embrace of acellular pertussis vaccines, a heightened emphasis on booster immunization efforts, the broadening availability of combination vaccines containing pertussis, an increase in adult and maternal pertussis vaccinations, and the reinforcement of governmental immunization campaigns.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13023&type=smp

Which Drivers Are Supporting The Pertussis Vaccine Market Growth?

Increasing childbirth rates are propelling the expansion of the pertussis vaccine market. Childbirth refers to the process of giving birth to a child, marking the conclusion of pregnancy where the fetus develops within the mother’s uterus, and the start of a new life outside the womb. The pertussis vaccine is predominantly administered to children, offering protection against whooping cough and other severe, potentially life-threatening diseases. For example, a report published in January 2023 by the Centers for Disease Control and Prevention, a US-based national public health organization, revealed that the United States saw a 1% increase in registered births, reaching a total of 3,664,292, when compared to 2022. This upward trend in childbirth rates is therefore a key driver for the growth of the pertussis vaccine market.

How Is The Pertussis Vaccine Market Categorized Across Its Segment Groups?

The pertussis vaccine market covered in this report is segmented –

1) By Product Type: DTaP (Diphtheria, Tetanus and Acellular Pertussis) Vaccine, Tdap (Tetanus, Diphtheria and Pertussis) Vaccine

2) By Vaccine Type: Whole-Cell Vaccine, Acellular Vaccine

3) By Application: Children, Adults, Infants

4) By End-User: Vaccination Centers, Hospitals, Clinics

Subsegments:

1) By DTaP (Diphtheria, Tetanus, And Acellular Pertussis) Vaccine: Pediatric DTaP Vaccine, Combination Vaccines With DTaP

2) By Tdap (Tetanus, Diphtheria, And Pertussis) Vaccine: Adolescent Tdap Vaccine, Adult Tdap Vaccine

Which Trends Are Shaping Growth In The Pertussis Vaccine Market?

Leading companies operating within the pertussis vaccine market are concentrating on developing advanced immunization solutions and obtaining regulatory clearances to bolster maternal and infant protection against whooping cough. These efforts aim to enhance vaccine accessibility, broaden its recommended application during pregnancy, and diminish illness associated with pertussis among newborns. For instance, in January 2023, Sanofi S.A., a France-based biopharmaceutical company, received U.S. FDA approval for the expanded use of its Adacel (Tdap) vaccine during the third trimester of pregnancy, enabling maternal immunization to help protect infants younger than two months who are at highest risk of severe pertussis infection. This authorization empowers healthcare professionals to actively immunize pregnant individuals, thereby ensuring that protective antibodies are transferred to the newborn prior to delivery. Consequently, infants acquire early-life immunity against pertussis, bridging the immunity gap until they are eligible for their own immunizations.

Which Firms Are Influencing Competition In The Pertussis Vaccine Market?

Major companies operating in the pertussis vaccine market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Sanofi Pasteur SA, CSL Limited, Serum Institute of India, Biological E. Limited, Bharat Biotech International Limited, Panacea Biotec Limited, PT Bio Farma, Walvax Biotechnology Co. Ltd., Beijing Minhai Biotechnology Co. Ltd., Wuhan Institute of Biological Products, Changchun Changsheng Life Sciences, Changsheng Bio-Technology Co. Ltd., Chiron Corporation, Sinovac Biotech Ltd., Takeda Pharmaceutical Company, Novartis AG, Johnson & Johnson

Get The Full Pertussis Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

Which Region Is The Top Contributor To The Pertussis Vaccine Market By Share?

North America was the largest region in the pertussis vaccine market in 2025. The regions covered in the pertussis vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Pertussis Vaccine Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

Browse Through More Reports Similar to the Global Pertussis Vaccine Market 2026, By The Business Research Company

Pertussis Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

Porcine Epidemic Diarrhea Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Pertussis Vaccine Market Over The 2026–2030 Period?

The pertussis vaccine market size has experienced consistent expansion in recent times. It is anticipated to grow from $5.65 billion in 2025 to $5.82 billion in 2026, reflecting a compound annual growth rate (CAGR) of 2.9%. The market’s historical development can be attributed to high childhood immunization coverage, national vaccination programs led by governments, past occurrences of whooping cough outbreaks, the integration of the pertussis vaccine into standard immunization schedules, and the availability of whole-cell vaccines.

The pertussis vaccine market size is anticipated to experience consistent expansion in the coming years. It is projected to reach $6.82 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.1%. This growth during the projected timeframe is attributable to several factors, including heightened awareness regarding adult pertussis vaccination, an uptick in maternal immunization recommendations, continuous progress in vaccine safety and efficacy, broadened healthcare accessibility within developing economies, and increased development of combination vaccines. Key trends shaping the forecast period encompass a growing uptake of acellular pertussis vaccines, an intensified emphasis on booster immunization programs, the wider availability of combination vaccines incorporating pertussis, an increase in adult and maternal pertussis vaccinations, and reinforced government immunization initiatives.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13023&type=smp

Which Economic Or Industry Drivers Are Impacting The Pertussis Vaccine Market?

The increasing number of births is propelling the expansion of the pertussis vaccine market into the future. Childbirth refers to the process of a mother delivering a baby, which concludes pregnancy, a period where a fetus grows inside the uterus, initiating the baby’s life beyond the womb. The pertussis vaccine is mainly administered to children to safeguard them against whooping cough and various other serious, potentially fatal illnesses. For example, data from January 2023, sourced from a report by the Centers for Disease Control and Prevention, a national public health body in the US, indicated that the United States experienced a 1% rise in recorded births, reaching a total of 3,664,292, relative to the figures from 2022. Thus, the growing childbirth rates are boosting the expansion of the pertussis vaccine market.

How Is The Pertussis Vaccine Market Segmented Across Key Categories?

The pertussis vaccine market covered in this report is segmented –

1) By Product Type: DTaP (Diphtheria, Tetanus and Acellular Pertussis) Vaccine, Tdap (Tetanus, Diphtheria and Pertussis) Vaccine

2) By Vaccine Type: Whole-Cell Vaccine, Acellular Vaccine

3) By Application: Children, Adults, Infants

4) By End-User: Vaccination Centers, Hospitals, Clinics

Subsegments:

1) By DTaP (Diphtheria, Tetanus, And Acellular Pertussis) Vaccine: Pediatric DTaP Vaccine, Combination Vaccines With DTaP

2) By Tdap (Tetanus, Diphtheria, And Pertussis) Vaccine: Adolescent Tdap Vaccine, Adult Tdap Vaccine

Which Upcoming Trends Are Expected To Influence The Pertussis Vaccine Market?

Leading firms within the pertussis vaccine market are concentrating their efforts on creating sophisticated immunization remedies and obtaining necessary regulatory clearances to bolster maternal and infant defense against whooping cough. Such endeavors seek to boost vaccine availability, broaden its advised application during pregnancy, and diminish pertussis-associated illness in newborns. Illustratively, in January 2023, Sanofi S.A., a biopharmaceutical entity based in France, obtained U.S. FDA authorization for the wider application of its Adacel (Tdap) vaccine during the third trimester of pregnancy, thereby facilitating maternal immunization to assist in safeguarding infants under two months old who face the highest risk of severe pertussis infection. This sanction empowers healthcare practitioners to actively immunize expectant mothers, guaranteeing the transfer of protective antibodies to the newborn prior to delivery. Consequently, infants acquire early protection against pertussis, bridging the immunity deficit until they are eligible for their own immunizations.

Who Are The Dominant Players Shaping The Pertussis Vaccine Market Landscape?

Major companies operating in the pertussis vaccine market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Sanofi Pasteur SA, CSL Limited, Serum Institute of India, Biological E. Limited, Bharat Biotech International Limited, Panacea Biotec Limited, PT Bio Farma, Walvax Biotechnology Co. Ltd., Beijing Minhai Biotechnology Co. Ltd., Wuhan Institute of Biological Products, Changchun Changsheng Life Sciences, Changsheng Bio-Technology Co. Ltd., Chiron Corporation, Sinovac Biotech Ltd., Takeda Pharmaceutical Company, Novartis AG, Johnson & Johnson

Read the full pertussis vaccine market report here:

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

What Are The Top-Performing Regions Within The Pertussis Vaccine Market?

North America was the largest region in the pertussis vaccine market in 2025. The regions covered in the pertussis vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Pertussis Vaccine Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13023&type=smp

Browse Through More Reports Similar to the Global Pertussis Vaccine Market 2026, By The Business Research Company

Pertussis Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

Porcine Epidemic Diarrhea Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the pertussis vaccine market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Pertussis Vaccine Market in 2026, and what figure is it projected to hit by 2030?

The pertussis vaccine market has experienced consistent growth in recent years. It is anticipated to expand from $5.65 billion in 2025 to $5.82 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 2.9%. In the past, this market’s expansion was influenced by high childhood immunization coverage, government-led national vaccination programs, historical outbreaks of whooping cough, the integration of the pertussis vaccine into routine immunization schedules, and the availability of whole-cell vaccines.

The pertussis vaccine market is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach a valuation of $6.82 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.1%. Factors contributing to this anticipated growth include heightened awareness regarding adult pertussis vaccination, an increase in recommendations for maternal immunization, improvements in vaccine safety and efficacy, wider access to healthcare in developing nations, and the progression of combination vaccine development. Key trends expected during this period involve a greater uptake of acellular pertussis vaccines, an enhanced emphasis on booster immunization strategies, the broadened availability of combination vaccines incorporating pertussis, an increase in adult and maternal pertussis vaccinations, and reinforced governmental immunization efforts.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13023&type=smp

Which Drivers Are Affecting Market Participation In The Pertussis Vaccine Market?

The increasing number of births is propelling the expansion of the pertussis vaccine market in the future. Childbirth refers to the process of a mother delivering a baby. This event represents the conclusion of pregnancy, a period where the fetus matures inside the mother’s womb, signaling the commencement of a child’s life beyond it. The pertussis vaccine is predominantly administered to children as it offers protection against whooping cough and other serious, potentially fatal illnesses. As an illustration, data from January 2023, reported by the US-based national public health entity, the Centers for Disease Control and Prevention, indicated that the United States experienced a 1% rise in recorded births, reaching a total of 3,664,292, when contrasted with the previous year, 2022. Consequently, the growing number of births is fueling the expansion of the pertussis vaccine market.

What Segment Classifications Make Up The Pertussis Vaccine Market?

The pertussis vaccine market covered in this report is segmented –

1) By Product Type: DTaP (Diphtheria, Tetanus and Acellular Pertussis) Vaccine, Tdap (Tetanus, Diphtheria and Pertussis) Vaccine

2) By Vaccine Type: Whole-Cell Vaccine, Acellular Vaccine

3) By Application: Children, Adults, Infants

4) By End-User: Vaccination Centers, Hospitals, Clinics

Subsegments:

1) By DTaP (Diphtheria, Tetanus, And Acellular Pertussis) Vaccine: Pediatric DTaP Vaccine, Combination Vaccines With DTaP

2) By Tdap (Tetanus, Diphtheria, And Pertussis) Vaccine: Adolescent Tdap Vaccine, Adult Tdap Vaccine

What Long-Term Trends Are Expected To Shape The Future Of The Pertussis Vaccine Market?

Key companies operating in the pertussis vaccine market are prioritizing the development of advanced immunization solutions and securing necessary regulatory approvals to enhance the protection of mothers and infants against whooping cough. These endeavors are focused on improving vaccine accessibility, extending its recommended use during pregnancy, and reducing pertussis-related illness in newborns. For instance, in January 2023, Sanofi S.A., a France-based biopharmaceutical company, received U.S. FDA approval for the broader use of its Adacel (Tdap) vaccine during the third trimester of pregnancy. This enables maternal immunization to help protect infants younger than two months, who are most vulnerable to severe pertussis infection. This approval empowers healthcare providers to actively immunize pregnant individuals, ensuring that protective antibodies are passed to the newborn before birth. As a result, infants gain early-life protection against pertussis, bridging the immunity gap until they can receive their own scheduled vaccinations.

Which Key Market Players Are Investing In Expansion And Innovation Within The Pertussis Vaccine Market?

Major companies operating in the pertussis vaccine market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Sanofi Pasteur SA, CSL Limited, Serum Institute of India, Biological E. Limited, Bharat Biotech International Limited, Panacea Biotec Limited, PT Bio Farma, Walvax Biotechnology Co. Ltd., Beijing Minhai Biotechnology Co. Ltd., Wuhan Institute of Biological Products, Changchun Changsheng Life Sciences, Changsheng Bio-Technology Co. Ltd., Chiron Corporation, Sinovac Biotech Ltd., Takeda Pharmaceutical Company, Novartis AG, Johnson & Johnson

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

Which Regions Are Poised For Strategic Growth In The Pertussis Vaccine Market?

North America was the largest region in the pertussis vaccine market in 2025. The regions covered in the pertussis vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pertussis Vaccine Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13023&type=smp

Browse Through More Reports Similar to the Global Pertussis Vaccine Market 2026, By The Business Research Company

Pertussis Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

Porcine Epidemic Diarrhea Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the pertussis vaccine market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Pertussis Vaccine Market Size?

The pertussis vaccine market has seen consistent expansion in recent years. Its value is projected to climb from $5.5 billion in 2024 to $5.65 billion in 2025, indicating a compound annual growth rate (CAGR) of 2.9%. In the past, this growth was primarily influenced by factors including disease prevalence, the existence of immunization programs, widespread pediatric vaccination, and various regulatory approvals.

The pertussis vaccine market size is anticipated to demonstrate continuous growth over the upcoming years. It is projected to expand to $6.49 billion by 2029, achieving a compound annual growth rate (CAGR) of 3.5%. The expansion during this forecast period is primarily driven by factors such as booster vaccination, maternal immunization, immunization programs for healthcare workers, and various global health initiatives. Key trends expected in the forecast period encompass personalized immunization schedules, the development of combination vaccines, initiatives aimed at vaccine equity, and the integration of digital health solutions for immunization.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13023&type=smp

What Core Market Drivers Are Expanding The Pertussis Vaccine Industry?

The expanding rate of childbirth is anticipated to fuel the growth of the pertussis vaccine market. Childbirth describes the process of a woman giving birth, representing the completion of pregnancy where a fetus develops in the uterus and initiates life outside the womb. The pertussis vaccine is predominantly administered to children to shield them from whooping cough and various severe, potentially fatal conditions. For example, in January 2023, the Centers for Disease Control and Prevention, a US-based national public health organization, released a report indicating that the United States saw a 1% rise in registered births, amounting to 3,664,292, compared to the prior year. Thus, the increasing childbirth rates are a significant impetus for the growth of the pertussis vaccine market.

What Segment Insights Are Highlighted In The Pertussis Vaccine Market Report?

The pertussis vaccine market covered in this report is segmented –

1) By Product Type: DTaP (Diphtheria, Tetanus and Acellular Pertussis) Vaccine, Tdap (Tetanus, Diphtheria and Pertussis) Vaccine

2) By Vaccine Type: Whole-Cell Vaccine, Acellular Vaccine

3) By Application: Children, Adults, Infants

4) By End-User: Vaccination Centers, Hospitals, Clinics

Subsegments:

1) By DTaP (Diphtheria, Tetanus, And Acellular Pertussis) Vaccine: Pediatric DTaP Vaccine, Combination Vaccines With DTaP

2) By Tdap (Tetanus, Diphtheria, And Pertussis) Vaccine: Adolescent Tdap Vaccine, Adult Tdap Vaccine

Which Notable Trends Are Transforming The Pertussis Vaccine Market Outlook?

Leading companies within the pertussis vaccine market are focused on creating novel medications and securing necessary approvals to maintain their competitive standing. As an example, in October 2022, the UK-headquartered pharmaceutical and biotechnology firm, GSK plc., disclosed the approval of BOOSTRIX by the U.S. Food and Drug Administration (FDA). BOOSTRIX is identified as a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap). This vaccine is administered during pregnancy to protect newborn infants from pertussis (whooping cough). Administration involves a single injection into the upper arm muscle. BOOSTRIX has been demonstrated to be both safe and effective for expectant mothers and their babies. Furthermore, it provides effective protection against pertussis, extending to severe instances of the illness.

Which Firms Are Driving Innovation Within The Pertussis Vaccine Market?

Major companies operating in the pertussis vaccine market are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Novartis AG, GlaxoSmithKline PLC, AstraZeneca PLC, BioNTech SE, Moderna Inc., Sinovac Biotech Ltd., CSL Limited, Astellas Pharma US Inc., Sanofi Pasteur SA, Mitsubishi Tanabe Pharma America Inc., PT Kalbe Farma Tbk, CSL Seqirus, Walvax Biotechnology Co.Ltd., Biological E. Limited, Serum Institute of India, Bavarian Nordic AS, PT Bio Farma, Bharat Biotech International Limited, Takeda Pharmaceutical Company, Panacea Biotec Limited, Beijing Minhai Biotechnology Co. Ltd., Protein Sciences Corporation, Wuhan Institute of Biological Products, Changchun Changsheng Life Sciences, Changsheng Bio-Technology Co. Ltd., Gennova Biopharmaceuticals Ltd., Chiron Corporation.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

What Regional Trends Are Shaping Growth In The Pertussis Vaccine Market?

North America was the largest region in the pertussis vaccine market in 2024. The regions covered in pertussis vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=13023&type=smp

Browse Through More Reports Similar to the Global Pertussis Vaccine Market 2025, By The Business Research Company

Cancer Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Dtp Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

Companion Animal Veterinary Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/companion-animal-veterinary-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What CAGR And Valuation Are Anticipated For The Pertussis Vaccine Market?

The market size for the pertussis vaccine has consistently expanded over the past few years. From 2024 to 2025, the projection indicates a rise from $5.5 billion to $5.65 billion, with a compound annual growth rate (CAGR) of 2.9%. Factors that contributed to the growth in the historic period include the prevalence of the disease, implementation of immunization programs, pediatric vaccination practices, and regulatory approvals.

In the coming years, the market size for the pertussis vaccine is anticipated to show consistent expansion. It’s projected to escalate to “$6.49 billion by 2029, with a compound annual growth rate (CAGR) of 3.5%. The surge over the forecast period can be accounted to factors such as booster vaccination, maternal immunization, immunization for healthcare workers, and worldwide health initiatives. During the forecast period, prominent trends will comprise personalized immunization schedules, combined vaccines, initiatives for vaccine equality, and the use of digital health in immunization.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13023&type=smp

Which Industry Forces Are Driving The Pertussis Vaccine Market Forward?

The pertussis vaccine market is witnessing significant growth due to an increase in childbirth rates. The process of delivering a child, also known as childbirth, signifies the end of pregnancy and the start of a new life outside the womb. The primary use of the pertussis vaccine is for children as it offers them protection against severe and possibly fatal diseases like whooping cough. A report by the Centers for Disease Control and Prevention, a public health organization based in the US, stated that in January 2023, there was a 1% rise in registered births, reaching a total of 3,664,292, in comparison to the previous year in the United States. Therefore, it can be presented that the increasing rate of childbirth is fueling the growth of the pertussis vaccine market.

What Segmentation Insights Are Provided In The Pertussis Vaccine Market Research?

The pertussis vaccine market covered in this report is segmented –

1) By Product Type: DTaP (Diphtheria, Tetanus and Acellular Pertussis) Vaccine, Tdap (Tetanus, Diphtheria and Pertussis) Vaccine

2) By Vaccine Type: Whole-Cell Vaccine, Acellular Vaccine

3) By Application: Children, Adults, Infants

4) By End-User: Vaccination Centers, Hospitals, Clinics

Subsegments:

1) By DTaP (Diphtheria, Tetanus, And Acellular Pertussis) Vaccine: Pediatric DTaP Vaccine, Combination Vaccines With DTaP

2) By Tdap (Tetanus, Diphtheria, And Pertussis) Vaccine: Adolescent Tdap Vaccine, Adult Tdap Vaccine

Which Notable Trends Are Transforming The Pertussis Vaccine Market Outlook?

Leading firms in the pertussis vaccine market are creating unique drugs and obtaining official approvals to maintain their market stature. For instance, GSK plc., a pharmaceutical and biotech company based in the UK, disclosed in October 2022 that the U.S. Food and Drug Administration (FDA) gave approval for BOOSTRIX. This vaccine is a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap). Used during pregnancy, it offers protection against pertussis, also known as whooping cough, in newborn infants through a single injection in the upper arm muscle. Evidently safe and beneficial for expectant mothers and their offspring, Boostrix is also effective in averting pertussis, even in its severe forms.

Which Firms Are Driving Innovation Within The Pertussis Vaccine Market?

Major companies operating in the pertussis vaccine market are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Novartis AG, GlaxoSmithKline PLC, AstraZeneca PLC, BioNTech SE, Moderna Inc., Sinovac Biotech Ltd., CSL Limited, Astellas Pharma US Inc., Sanofi Pasteur SA, Mitsubishi Tanabe Pharma America Inc., PT Kalbe Farma Tbk, CSL Seqirus, Walvax Biotechnology Co.Ltd., Biological E. Limited, Serum Institute of India, Bavarian Nordic AS, PT Bio Farma, Bharat Biotech International Limited, Takeda Pharmaceutical Company, Panacea Biotec Limited, Beijing Minhai Biotechnology Co. Ltd., Protein Sciences Corporation, Wuhan Institute of Biological Products, Changchun Changsheng Life Sciences, Changsheng Bio-Technology Co. Ltd., Gennova Biopharmaceuticals Ltd., Chiron Corporation.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Pertussis Vaccine Market?

North America was the largest region in the pertussis vaccine market in 2024. The regions covered in pertussis vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13023&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Pertussis Vaccine Market Evolve in Terms of Growth and Size by 2029?

In recent times, the market for the pertussis vaccine has seen consistent growth. The market is projected to increase from $5.5 billion in 2024 to $5.65 billion in 2025, expanding at a compound annual growth rate (CAGR) of 2.9%. The historical growth has been driven by factors such as disease prevalence, immunization schemes, pediatric vaccinations, and regulatory approvals.

The market for the pertussis vaccine is anticipated to experience consistent expansion in the coming years, with projections predicting its growth to “$6.49 billion in 2029, boasting a compound annual growth rate (CAGR) of 3.5%. The projected growth in this timeframe can be connected to factors such as booster vaccination, maternal immunization, immunization of healthcare workers, and global health initiatives. Key trends anticipated for the forecast period are personalized immunization schedules, combination vaccines, initiatives for the equitable distribution of vaccines, and the application of digital health technology in immunization processes.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13023&type=smp

What factors are expected to fuel Pertussis Vaccine market growth in the coming years?

The escalation in birth rates is fueling the expansion of the pertussis vaccine market. Giving birth to a child, also known as childbirth, symbolizes the start of an independent life for the child outside the mother’s womb, after being developed in the uterus. The main usage of the pertussis vaccine is in newborns as it guards against whooping cough and other serious or potentially lethal illnesses. For example, the Centers for Disease Control and Prevention, a national public health organization based in the US, reported in January 2023 that there was a surge of 1% in recorded births, amounting to 3,664,292, compared to the preceding year. Consequently, the surging birth rates are propelling the pertussis vaccine market’s development.

The pertussis vaccine market covered in this report is segmented –

1) By Product Type: DTaP (Diphtheria, Tetanus and Acellular Pertussis) Vaccine, Tdap (Tetanus, Diphtheria and Pertussis) Vaccine

2) By Vaccine Type: Whole-Cell Vaccine, Acellular Vaccine

3) By Application: Children, Adults, Infants

4) By End-User: Vaccination Centers, Hospitals, Clinics

Subsegments:

1) By DTaP (Diphtheria, Tetanus, And Acellular Pertussis) Vaccine: Pediatric DTaP Vaccine, Combination Vaccines With DTaP

2) By Tdap (Tetanus, Diphtheria, And Pertussis) Vaccine: Adolescent Tdap Vaccine, Adult Tdap Vaccine

What Trends Are Currently Influencing Growth In The Pertussis Vaccine Market?

Leading firms in the pertussis vaccine market are creating novel medicines and gaining regulatory approvals to maintain their market presence. For example, GSK plc., a pharma and biotech company based in the UK, revealed in October 2022 that the U.S. Food and Drug Administration (FDA) had approved BOOSTRIX. This vaccine, which is an adsorbed tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine, is administered during pregnancy to protect newborns from contracting pertussis, also known as whooping cough. It is given via a single injection into the upper arm muscle. Boostrix has been proven safe and efficient for expectant women and their newborns, with a successful track record in preventing pertussis, even its severe forms.

What Are The Most Active Companies In The Pertussis Vaccine Market Today?

Major companies operating in the pertussis vaccine market are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Novartis AG, GlaxoSmithKline PLC, AstraZeneca PLC, BioNTech SE, Moderna Inc., Sinovac Biotech Ltd., CSL Limited, Astellas Pharma US Inc., Sanofi Pasteur SA, Mitsubishi Tanabe Pharma America Inc., PT Kalbe Farma Tbk, CSL Seqirus, Walvax Biotechnology Co.Ltd., Biological E. Limited, Serum Institute of India, Bavarian Nordic AS, PT Bio Farma, Bharat Biotech International Limited, Takeda Pharmaceutical Company, Panacea Biotec Limited, Beijing Minhai Biotechnology Co. Ltd., Protein Sciences Corporation, Wuhan Institute of Biological Products, Changchun Changsheng Life Sciences, Changsheng Bio-Technology Co. Ltd., Gennova Biopharmaceuticals Ltd., Chiron Corporation.

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

Which Regional Markets Are Attracting The Most Investment In Pertussis Vaccine?

North America was the largest region in the pertussis vaccine market in 2024. The regions covered in pertussis vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13023&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Pertussis Vaccine Market Growth Evolved From 2024 To 2025, And What’s Ahead?

In recent times, we have observed a constant growth in the size of the pertussis vaccine market. Predictions indicate an increase from $5.5 billion in 2024, to $5.65 billion in 2025, which signifies a compound annual growth rate (CAGR) of 2.9%. Factors such as disease prevalence, immunization schemes, pediatric vaccination, and regulatory approvals, have contributed to the growth we’ve seen in the historic period.

The market size for the pertussis vaccine is predicted to experience consistent growth in the forthcoming years, reaching $6.49 billion in 2029 with a compound annual growth rate (CAGR) of 3.5%. The expected growth in the forecast period can be linked to factors such as booster vaccinations, maternal immunizations, immunizations for healthcare workers, and worldwide health initiatives. Noteworthy trends for the predicted period involve personalized vaccine schedules, combination vaccines, initiatives to equalize vaccine access, and the use of digital health for immunization.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13023&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Pertussis Vaccine Market?

The increase in birth rates is propelling the expansion of the pertussis vaccine market. Childbirth, the process of delivering a baby, signifies the end of pregnancy and the start of a new existence outside the womb. The pertussis vaccine is predominantly administered to children as it safeguards them from whooping cough and other dangerous diseases that could be lethal. For example, in January 2023, a report from the Centers for Disease Control and Prevention, a public health institution in the US, revealed a 1% rise in recorded births in the United States, amounting to 3,664,292 in comparison to the prior year. As a result, the escalating birth rates are fueling the pertussis vaccine market’s expansion.

Which Primary Segments of the Pertussis Vaccine Market Are Driving Growth and Industry Transformations?

The pertussis vaccine market covered in this report is segmented –

1) By Product Type: DTaP (Diphtheria, Tetanus and Acellular Pertussis) Vaccine, Tdap (Tetanus, Diphtheria and Pertussis) Vaccine

2) By Vaccine Type: Whole-Cell Vaccine, Acellular Vaccine

3) By Application: Children, Adults, Infants

4) By End-User: Vaccination Centers, Hospitals, Clinics

Subsegments:

1) By DTaP (Diphtheria, Tetanus, And Acellular Pertussis) Vaccine: Pediatric DTaP Vaccine, Combination Vaccines With DTaP

2) By Tdap (Tetanus, Diphtheria, And Pertussis) Vaccine: Adolescent Tdap Vaccine, Adult Tdap Vaccine

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13023&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Pertussis Vaccine Market?# Market?

North America was the largest region in the pertussis vaccine market in 2024. The regions covered in pertussis vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Most Significant Market Trends in the Pertussis Vaccine Market?

Leading firms in the pertussis vaccine market, such as UK-based GSK plc, are actively developing groundbreaking drugs and gaining necessary approvals to maintain their market dominance. As an example, in October 2022, the U.S. Food and Drug Administration (FDA) gave approval to the company’s BOOSTRIX, a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap). This vaccine, which is administered by injection into the upper arm muscle, is utilized during pregnancy to protect newborn infants from pertussis (whooping cough). Studies have shown that Boostrix is not only safe and effective for pregnant women and their offspring, but it also effectively combats pertussis, including its severe forms.

View the full report here:

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

What Parameters Are Used to Define the Pertussis Vaccine Market?

The pertussis vaccine refers to a vaccine that protects against whooping cough (pertussis), which is a highly contagious respiratory disease caused by the bacterium Bordetella pertussis. It is designed to stimulate the immune system to produce protective antibodies against the pertussis bacterium, thus reducing the risk of infection and its associated symptoms.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13023

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model